Summary
The antitumor activity of cis-dihalogenobis(1-phenyl-1,3-butanedionato)titanium(IV) compounds against L 1210 leukemia as compared with cis-diamminedichloroplatinum(II) (Cisplatin, cis-DDP, NSC 119875) was investigated. The tested compounds showed an enhanced effect and a lower toxicity compared with Cisplatin.
This is a preview of subscription content, log in via an institution to check access.
References
Hill JM, Loeb E, MacLellan A, Hill NO, Khan A, King JJ (1975) Clinical studies of platinum coordination compounds in the treatment of various malignant diseases. Cancer Chemother Rep 59:647–659
Köpf-Maier P, Hesse B, Köpf H (1980) Tumorhemmung durch Metallocene: Wirkung von Titanocen-, Zirkonocen- und hafnocendichlorid gegenüber Ehrlich-Ascites-Tumor der Maus. J Cancer Res Clin Oncol 96:43–51
Madjos NE, Harrinston CT (1978) Platinum Nephrotoxicity. Am J Med 65: 307–314
Pinedo HM (1979) Cancer chemotherapy. Excerpta Medica, Amsterdam Oxford pp 107–125
Serpone N, Fay RC (1967) Stereochemistry and lability of dihalobis(β-diketonato)-titanium(IV) complexes, II benzoylacetonates and dibenzoylmethanates. Inorg Chem 6:1835–1843
Speer RJ, Ridgway H, Hall LM, Stewart PD, Howe KE, Lieberman DZ, Newman AP, Hill JM (1975) Coordination complexes of platinum as antitumour agents. Cancer Chemother Rep 59:629–641
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Keller, H.J., Keppler, B. & Schmähl, D. Antitumor activity of cis-dihalogenobis(1-phenyl-1,3-butanedionato)titanium(IV) compounds. J Cancer Res Clin Oncol 105, 109–110 (1983). https://doi.org/10.1007/BF00391842
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00391842